Literature DB >> 15654910

Single-agent thalidomide induces response in T-cell lymphoma.

G Damaj1, R Bouabdallah, N Vey, K Bilger, M Mohty, J A Gastaut.   

Abstract

T-cell lymphoma is an aggressive lymphoma that cannot be cured despite aggressive therapy, including autologous stem cell transplantation. Thalidomide is an immunomodulatory drug with numerous properties that has proven effective in relapsed multiple myeloma and, to a lesser extent, in other hematologic diseases. We report three cases of relapsed refractory T-cell lymphoma treated with thalidomide with a good tumor response. (c) Blackwell Munksgaard 2005

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15654910     DOI: 10.1111/j.1600-0609.2004.00362.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  2 in total

1.  Thalidomide plus chemotherapy exhibit enhanced efficacy in the clinical treatment of T-cell non-Hodgkin's lymphoma: A prospective study of 46 cases.

Authors:  Hongyang Wu; Chenchen Zhao; Kangsheng Gu; Yang Jiao; Jiqing Hao; Guoping Sun
Journal:  Mol Clin Oncol       Date:  2014-06-06

2.  [Clinical analysis of thalidomide in 36 untreated patients with T-cell lymphoma].

Authors:  H Y Huang; Y Q Song; W Zheng; X P Wang; Y Xie; N J Lin; M F Tu; C Zhang; L Y Ping; W P Liu; Z T Ying; L J Deng; N Ding; M Wu; Y L Sun; T T Du; X Leng; J Zhu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2016-06-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.